[Renal toxicity of anti-VEGF (corrected) targeted therapies].


For a few years, new targeted therapies have been used for metastatic cancers, targeting VEGF and its receptors and improving patients' survival for metastatic carcinoma (kidney, GIST, breast, colorectal). The objective of these treatments is to block either circulating VEGF (bevacizumab; VEGF-Trap), or tyrosine kinase receptors (especially the VEGF… (More)
DOI: 10.1016/j.nephro.2012.10.003


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.